scispace - formally typeset
J

Justin D. Lathia

Researcher at Cleveland Clinic Lerner Research Institute

Publications -  301
Citations -  19033

Justin D. Lathia is an academic researcher from Cleveland Clinic Lerner Research Institute. The author has contributed to research in topics: Cancer stem cell & Stem cell. The author has an hindex of 59, co-authored 247 publications receiving 15245 citations. Previous affiliations of Justin D. Lathia include Cleveland Clinic & Duke University.

Papers
More filters
Journal ArticleDOI

Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

TL;DR: It is demonstrated that hypoxia-inducible factor HIF2alpha and multiple HIF-regulated genes are preferentially expressed in GSCs in comparison to non-stem tumor cells and normal neural progenitors.
Journal ArticleDOI

Cancer stem cells in glioblastoma

TL;DR: To fulfill the future goal of developing novel therapies to collapse CSC dynamics, drawing parallels to other normal and pathological states that are highly interactive with their microenvironments and that use developmental signaling pathways will be beneficial.
Journal ArticleDOI

Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth

TL;DR: It is shown that GSCs give rise to pericytes to support vessel function and tumor growth, and therapeutic targeting of GSC-derived pericyts may effectively block tumor progression and improve antiangiogenic therapy.
Journal ArticleDOI

Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits

TL;DR: It is reported that neurons express several TLRs, and that the levels of TLR2 and -4 are increased in neurons in response to IFN-γ stimulation and energy deprivation, establishing a proapoptotic signaling pathway for TLR1 and -3 in neurons that may render them vulnerable to ischemic death.
Journal ArticleDOI

Integrin Alpha 6 regulates glioblastoma stem cells

TL;DR: Evidence is provided that GSCs express high levels of integrin alpha6, which can serve not only as an enrichment marker but also as a promising antiglioblastoma therapy, and this work identified integrinalpha6 as a candidate for anti-tumor therapy.